Beyond antibodies: New affinity reagents to unlock the proteome

Antibodies have been the workhorse reagents of protein capture and quantification since their 1959 debut in the RIAs developed by Yalow and Berson. However, there are technical challenges to the use of antibodies in highly multiplexed arrays aimed at measuring hundreds or even thousands of proteins at one time. We describe here a recently developed class of synthetic protein‐binding reagents (slow off‐rate modified aptamer). We discuss the chemical makeup and protein binding specifications of slow off‐rate modified aptamer reagents, compare them to traditional aptamers and antibodies, briefly describe the novel proteomic assay that takes advantage of their unique properties, and provide several examples of their multiple applications to biomarker discovery and validation across a range of biomedical science questions.

[1]  Tracy R. Keeney,et al.  Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.

[2]  S. Yokoyama,et al.  Anti-(Raf-1) RNA aptamers that inhibit Ras-induced Raf-1 activation. , 2002, European journal of biochemistry.

[3]  Maria P. Pavlou,et al.  The long journey of cancer biomarkers from the bench to the clinic. , 2013, Clinical chemistry.

[4]  S. Missailidis,et al.  Aptamers as inhibitors of target proteins , 2009, Expert opinion on therapeutic patents.

[5]  H. Hoogenboom,et al.  Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.

[6]  B. Haab.  Methods and applications of antibody microarrays in cancer research , 2003, Proteomics.

[7]  Stephen A. Williams,et al.  Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer , 2010, PloS one.

[8]  Rachel Ostroff,et al.  Life's simple measures: unlocking the proteome. , 2012, Journal of molecular biology.

[9]  N. Janjić,et al.  High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Rachel Ostroff,et al.  The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array. , 2010, Journal of proteomics.

[11]  John McCafferty,et al.  Beyond natural antibodies: the power of in vitro display technologies , 2011, Nature Biotechnology.

[12]  S. Berson,et al.  Assay of Plasma Insulin in Human Subjects by Immunological Methods , 1959, Nature.

[13]  N. Janjić,et al.  Detection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers. , 2013, Diagnostic microbiology and infectious disease.

[14]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[15]  Pei Wang,et al.  The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline , 2008, Proteomics. Clinical applications.

[16]  Dan Schneider,et al.  Expanding the chemistry of DNA for in vitro selection. , 2010, Journal of the American Chemical Society.

[17]  J. Foote,et al.  Kinetic and affinity limits on antibodies produced during immune responses. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Gold,et al.  Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. , 1996, Journal of molecular biology.

[19]  Vivien Marx,et al.  Finding the right antibody for the job , 2013, Nature Methods.

[20]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[21]  Sheri K. Wilcox,et al.  Protein Signature of Lung Cancer Tissues , 2012, PloS one.

[22]  Sheri K. Wilcox,et al.  Aptamers and the RNA world, past and present. , 2012, Cold Spring Harbor perspectives in biology.

[23]  M Yarus,et al.  Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.

[24]  J. Hopfield.  Kinetic proofreading: a new mechanism for reducing errors in biosynthetic processes requiring high specificity. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Barbas.  Synthetic human antibodies , 1995, Nature Medicine.

[26]  Tracy R. Keeney,et al.  Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array. , 2012, The American journal of pathology.

[27]  A. Pardi,et al.  High-resolution molecular discrimination by RNA. , 1994, Science.

[28]  J. Ninio.  Kinetic amplification of enzyme discrimination. , 1975, Biochimie.

[29]  P. T. Jones,et al.  Isolation of high affinity human antibodies directly from large synthetic repertoires. , 1994, The EMBO journal.

[30]  George G Klee,et al.  Antibody-based protein multiplex platforms: technical and operational challenges. , 2010, Clinical chemistry.

[31]  J. Frystyk,et al.  The current status of IGF-I assays--a 2009 update. , 2010, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[32]  Jonathan D. Vaught,et al.  Measurement of Cetuximab and Panitumumab-Unbound Serum EGFR Extracellular Domain Using an Assay Based on Slow Off-Rate Modified Aptamer (SOMAmer) Reagents , 2013, PloS one.

[33]  Gary Walsh,et al.  Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.

[34]  A. Varki,et al.  DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. , 1996, The Journal of clinical investigation.

[35]  D. Bunka,et al.  Aptamers come of age – at last , 2006, Nature Reviews Microbiology.

[36]  R Thorpe,et al.  Immunoassays for detecting cytokines: what are they really measuring? , 1995, Journal of immunological methods.

[37]  J. Latham,et al.  The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2'-deoxyuridine. , 1994, Nucleic acids research.

[38]  G. Winter,et al.  Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.

[39]  Daniel O'Connell,et al.  Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets , 2012, Proceedings of the National Academy of Sciences.

[40]  Harald Schumny,et al.  Next generation , 2005, Comput. Stand. Interfaces.

[41]  Sheri K. Wilcox,et al.  Rapid Histochemistry Using Slow Off-rate Modified Aptamers With Anionic Competition , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[42]  C. Barbas,et al.  Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Jayasena.  Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.

[44]  K. Horii,et al.  Quantitative and sensitive protein detection strategies based on aptamers , 2012, Proteomics. Clinical applications.

[45]  Martina Rimmele,et al.  Nucleic Acid Aptamers as Tools and Drugs: Recent Developments , 2003, Chembiochem : a European journal of chemical biology.

[46]  Tracy R. Keeney,et al.  From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay , 2011, PloS one.

[47]  R. Stoltenburg,et al.  SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands. , 2007, Biomolecular engineering.

[48]  N. Janjić,et al.  Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. , 1994, Biochemistry.

[49]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[50]  B. Mumey,et al.  Antigen-antibody interface properties: composition, residue interactions, and features of 53 non-redundant structures. , 2012, Biochimica et biophysica acta.

[51]  Maria C. DeRosa,et al.  Challenges and Opportunities for Small Molecule Aptamer Development , 2012, Journal of nucleic acids.

[52]  S. Ringquist,et al.  Anti-L-selectin oligonucleotide ligands recognize CD62L-positive leukocytes: binding affinity and specificity of univalent and bivalent ligands. , 1998, Cytometry.

[53]  Stephen A. Williams,et al.  Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool , 2012, PloS one.

[54]  Richard T. Lee,et al.  Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy , 2013, Cell.

[55]  Yi Xiao,et al.  Probing the Limits of Aptamer Affinity with a Microfluidic SELEX Platform , 2011, PloS one.